Creating new antiviral treatments for COVID-19 using the body's immune response
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
This study is looking at how our body's natural defenses can fight the COVID-19 virus, with the goal of creating new treatments that might work better than what we have now, helping patients and potentially tackling other infections too.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10669717 on NIH RePORTER |
What this research studies
This research focuses on understanding how the body's type I interferon response can combat SARS-CoV-2, the virus responsible for COVID-19. By investigating the antiviral gene programs activated during infection, the researchers aim to develop broad-spectrum antiviral agents that could be effective against COVID-19 and other emerging infectious diseases. The approach involves studying the innate immune responses and leveraging this knowledge to create novel therapeutic agents. Patients may benefit from new treatment options that could be more effective than current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at risk of severe COVID-19 or have been diagnosed with the virus.
Not a fit: Patients who are not infected with SARS-CoV-2 or those with non-viral respiratory illnesses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective antiviral treatments for COVID-19 and other viral infections.
How similar studies have performed: Previous research has shown promise in developing antiviral agents based on immune responses, indicating potential for success in this novel approach.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Jung, Michael E — University of California Los Angeles
- Study coordinator: Jung, Michael E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.